ATE484522T1 - Menschliche antikörper gegen timp-1 - Google Patents

Menschliche antikörper gegen timp-1

Info

Publication number
ATE484522T1
ATE484522T1 AT02764308T AT02764308T ATE484522T1 AT E484522 T1 ATE484522 T1 AT E484522T1 AT 02764308 T AT02764308 T AT 02764308T AT 02764308 T AT02764308 T AT 02764308T AT E484522 T1 ATE484522 T1 AT E484522T1
Authority
AT
Austria
Prior art keywords
timp
human antibodies
fibrosis
disease
diagnose
Prior art date
Application number
AT02764308T
Other languages
English (en)
Inventor
Clark Pan
Andreas Knorr
Michael Schauer
Claudia Hirth-Dietrich
Sabine Kraft
Barbara Krebs
Original Assignee
Bayer Corp
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp, Morphosys Ag filed Critical Bayer Corp
Application granted granted Critical
Publication of ATE484522T1 publication Critical patent/ATE484522T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
AT02764308T 2001-04-24 2002-04-24 Menschliche antikörper gegen timp-1 ATE484522T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28568301P 2001-04-24 2001-04-24
PCT/US2002/012801 WO2002086085A2 (en) 2001-04-24 2002-04-24 Human timp-1 antibodies

Publications (1)

Publication Number Publication Date
ATE484522T1 true ATE484522T1 (de) 2010-10-15

Family

ID=23095281

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02764308T ATE484522T1 (de) 2001-04-24 2002-04-24 Menschliche antikörper gegen timp-1

Country Status (8)

Country Link
US (6) US7091323B2 (de)
EP (1) EP1381631B1 (de)
JP (2) JP4406206B2 (de)
AT (1) ATE484522T1 (de)
AU (1) AU2002307494A1 (de)
CA (1) CA2445168A1 (de)
DE (1) DE60237969D1 (de)
WO (1) WO2002086085A2 (de)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK85193D0 (da) * 1993-07-16 1993-07-16 Cancerforskningsfondet Af 1989 Suppression of inhibitors
US20060154245A1 (en) * 1999-04-09 2006-07-13 Rigshospitalet Method for detecting, screening and/or montoring a cancer in individual
NZ515311A (en) 1999-04-09 2002-11-26 Rigshospitalet Mass screening and highly specific early identification of colorectal or metastatic breast cancer by measuring TIMP-1 tissue inhibitor
US7374886B2 (en) 1999-04-09 2008-05-20 Rigshospitalet Tissue inhibitor of matrix metalloproteinases type-1 (TIMP-1) as a cancer marker and postoperative marker for minimal residual disease or recurrent disease in patients with a prior history of cancer
AU2002307494A1 (en) * 2001-04-24 2002-11-05 Bayer Corporation Human timp-1 antibodies
US7438907B2 (en) * 2002-11-15 2008-10-21 Genmab A/S Human monoclonal antibodies against CD25
JP2004198419A (ja) * 2002-12-13 2004-07-15 Bayer Healthcare Llc Ｔｉｍｐ１を用いた検出方法
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
KR20130065723A (ko) 2003-06-27 2013-06-19 암젠 프레몬트 인코포레이티드 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그 용도
JP2007528721A (ja) 2003-08-14 2007-10-18 ダイアックス コーポレイション エンドセリアーゼ−２リガンド
WO2005030793A2 (en) 2003-09-24 2005-04-07 Millennium Pharmaceuticals, Inc. Antibodies which bind human cxcr3
AU2005235811B2 (en) * 2004-02-06 2011-11-03 Morphosys Ag Anti-CD38 human antibodies and uses therefor
US9200061B2 (en) 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
KR20140066259A (ko) * 2004-02-06 2014-05-30 모르포시스 아게 항-ｃｄ３８ 인간 항체 및 그의 용도
CA2561835A1 (en) * 2004-03-30 2005-10-13 Den Kgl. Veterinaer-Og Landbohojskole Improvements in cancer treatment and cancer treatment efficacy prediction by blocking and detecting protease inhibitors
GB0420771D0 (en) * 2004-09-17 2004-10-20 Randox Lab Ltd Antibody
TW200745162A (en) * 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
JP5142458B2 (ja) * 2005-06-30 2013-02-13 キヤノン株式会社 標的物質捕捉分子、標的物質捕捉用の素子、これらを用いた標的物質検出用の装置及びキット、並びに、標的物質の検出方法
CA2625681C (en) 2005-10-12 2016-08-02 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
CA2628221A1 (en) 2005-10-31 2007-05-10 Oncomed Pharmaceuticals, Inc. Anti-frizzled receptor antibodies for treating cancer
AR060017A1 (es) * 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
ES2413087T3 (es) 2006-06-13 2013-07-15 Oncomed Pharmaceuticals, Inc. Composiciones y métodos para el diagnóstico y tratamiento del cáncer
ES2397661T3 (es) * 2006-08-04 2013-03-08 Isis Pharmaceuticals, Inc. Composiciones y sus usos dirigidos a la diacilglicerol aciltransferasa 1
WO2008091641A2 (en) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
EP1997830A1 (de) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
CN101855243A (zh) * 2007-09-20 2010-10-06 伯拉考成像股份公司 用于制备新的寡克隆抗体的方法
TWI489993B (zh) * 2007-10-12 2015-07-01 Novartis Ag 骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）抗體組合物及使用方法
EP3115469B1 (de) * 2007-11-19 2020-04-29 Celera Corporation Lungenkrebsmarker und verwendungen davon
WO2009127691A1 (en) * 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
CN102112490B (zh) 2008-07-08 2014-10-22 昂考梅德药品有限公司 Notch1受体结合剂和其使用方法
AU2014201433B2 (en) * 2008-08-05 2016-05-26 Novartis Ag Compositions and methods for antibodies targeting complement protein C5
PY09026846A (es) * 2008-08-05 2015-09-01 Novartis Ag Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
SG190568A1 (en) 2008-09-26 2013-06-28 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
WO2010045495A2 (en) 2008-10-16 2010-04-22 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
EP2230251A1 (de) * 2009-03-19 2010-09-22 Bracco Imaging S.p.A Antikörper, die speziell im Koronarplaque aktiv sind und Verfahren zur ihrer Identifizierung
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
EP2493506B1 (de) * 2009-10-30 2019-04-10 Janssen Biotech, Inc. Il-17a-antagonisten
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
CA2794674A1 (en) 2010-04-01 2011-10-06 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
ES2728278T3 (es) 2011-12-21 2019-10-23 Novartis Ag Composiciones que comprenden anticuerpos dirigidos al factor P y C5
AU2013334790A1 (en) 2012-10-23 2015-04-30 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using Wnt pathway-binding agents
AU2014212081A1 (en) 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
HK1219533A1 (zh) * 2013-03-15 2017-04-07 Intermune, Inc. 蛋白质组学ipf标志物
WO2015067277A1 (en) 2013-11-07 2015-05-14 University Of Copenhagen Timp-1 binding partner
EP3774919A4 (de) * 2018-03-30 2021-12-29 Eureka Therapeutics, Inc. Gegen cd22 gerichtete konstrukte und verwendungen davon
WO2021053490A1 (en) * 2019-09-16 2021-03-25 Novartis Ag Use of high-affinity, ligand-blocking, humanized anti-t-cell immunoglobulin domain and mucin domain-3 (tim-3) igg4 antibody for the treatment of myelofibrosis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK169987D0 (da) 1987-04-03 1987-04-03 Jens Christian Jensenius Human tumor-associated antigen, ca-ou1
DE69120146T2 (de) * 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6093399A (en) 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US6004555A (en) 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US6036955A (en) 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
US5877289A (en) 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US5324634A (en) 1992-03-31 1994-06-28 The Research Foundation Of State University Of New York Diagnostic tests measuring gelatinase/inhibitor complexes for detection of aggressive and metastatic cancer
EP1262493A1 (de) 1992-10-29 2002-12-04 Bayer Corporation Diagnostischer Test spezifisch für die latente Matrix Metalloproteinase no. 9
JPH08134098A (ja) 1994-11-11 1996-05-28 Morinaga & Co Ltd ヒトｔｉｍｐ−１の高感度測定法
EP1117835A4 (de) 1998-10-02 2005-03-09 Genzyme Corp Adhäsionsprävention
NZ515311A (en) 1999-04-09 2002-11-26 Rigshospitalet Mass screening and highly specific early identification of colorectal or metastatic breast cancer by measuring TIMP-1 tissue inhibitor
AU2002307494A1 (en) * 2001-04-24 2002-11-05 Bayer Corporation Human timp-1 antibodies

Also Published As

Publication number Publication date
US20070160614A1 (en) 2007-07-12
JP2004529647A (ja) 2004-09-30
AU2002307494A1 (en) 2002-11-05
US20140086935A1 (en) 2014-03-27
DE60237969D1 (de) 2010-11-25
HK1061699A1 (en) 2004-09-30
US20110262429A1 (en) 2011-10-27
WO2002086085A3 (en) 2003-02-20
US20040105862A1 (en) 2004-06-03
US20130302340A1 (en) 2013-11-14
JP4406206B2 (ja) 2010-01-27
CA2445168A1 (en) 2002-10-31
US7432364B2 (en) 2008-10-07
WO2002086085A2 (en) 2002-10-31
JP4993779B2 (ja) 2012-08-08
US7993849B2 (en) 2011-08-09
EP1381631A4 (de) 2006-02-01
EP1381631B1 (de) 2010-10-13
US20090017037A1 (en) 2009-01-15
EP1381631A2 (de) 2004-01-21
JP2009195233A (ja) 2009-09-03
US7091323B2 (en) 2006-08-15

Similar Documents

Publication Publication Date Title
ATE484522T1 (de) Menschliche antikörper gegen timp-1
NO20080636L (no) Brukergrensesnitt for a opprette en regnearkdataoppsummeringstabell
GB2366800B (en) Antibody molecules having specificity for human tumor necrosis factor alpha,and use thereof
DK1893196T3 (da) Diarylhydantoin-forbindelse
DK1831362T3 (da) Syreaktive svampeproteaser
NO20035301D0 (no) Små molekyl¶re antagonister av proteiner i BCL-2-familien
NO20083062L (no) Humane monoklonale antistoffer mot fukosyl-GM1 og fremgangsmater for anvendelse av anti-fukosyl-GM1
EA200201214A1 (ru) Замещенные тиоацетамиды
NO20071378L (no) Tiazolo-naftylsyrer.
EA200100747A1 (ru) Способ востребования приобретателем исполнения обязательства, связанного с карточкой, и признания этого обязательства эмитентом
FR2831442B1 (fr) Composition cosmetique mimant le sebum, et utilisations
EA200401032A1 (ru) Антиинфарктные молекулы
SE0301987D0 (sv) New polypeptide
ITTV20040159A1 (it) Sistema di consultazione e trattamento di informazioni dedicate all'escursionismo con l'impiego di hardware standard pda.
ATE374947T1 (de) Bestimmung freier fraktionen
DK1973514T3 (da) Alkohol-i-olie-type-emulsion omfattende et multivalent metalsalt
Cole Simple answers to museum complexity.
Woo A Business Planning Process Model to Develope Successful Housing Project
ATE382098T1 (de) Zellbindende nukleinsäuremoleküle (aptamere)
TR200100219T2 (tr) IL-8 Reseptörü Antagonistleri
Rutherford An archaeology of Tudor poor law
장암 et al. BOOK & PEOPLE
Spinellis Code reading: the open source perspective, vol. 1.
Ellis Titillation and chippings
Altin Prof. Dr. Frank Eckardt/Ammalia Podlaszewska, M. Sc. 8 May 2016

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties